Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

PHASE3CompletedINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions
Bronchiectasis
Interventions
DRUG

AZLI

AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily

DRUG

Placebo

Placebo to match AZLI administered via nebulizer three times daily

Trial Locations (60)

2010

St. Vincent's Hospital, Darlinghurst

2037

Woolcock Institute of Medical Research, Glebe

2139

Concord Hospital, Concord

2145

Westmead Hospital, Westmead

2217

St. George Hospital, Kogarah

3168

Monash Medical Centre, Clayton

3194

Alfred Hospital, Westmead

3199

Peninsula Health, Frankston

4032

The Prince Charles Hospital, Chermside

4101

Mater Adult Hospital, Brisbane

5000

Royla Adelaide Hospital, Adelaide

5041

Repatriation General Hospital, Daws Park

5065

Respiratory Clinical Trials, Toorak Gardens

6000

Royal Perth Hospital, Perth

6009

Sir Charles Gairdner Hospital, Nedlands

10019

St. Luke's Roosevelt Hospital, New York

11418

Jamaica Hospital Medical Center, Jamaica

11501

Winthrop University Hospital - Clinical Trials Center, Mineola

12208

Albany Medical Center, Albany

19102

Drexel University College of Medicine, Philadelphia

19104

University of Pennsylvania Medical Center - Pulmonary, Allergy & Critical Care Division, Philadelphia

19107

Asthma Allergy & Pulmonary Associates, Philadelphia

21204

Pulmonary and Critical Care Associates of Baltimore, Baltimore

22042

Inova Fairfax Hospital/ Heart and Vascular Institute Advanced Lung Disease and Transplant Center, Falls Church

22908

University of Virginia Pulmonary and Critical Care, Charlottesville

29425

Medical University of South Carolina, Charleston

30342

Atlanta Pulmonary Group, Atlanta

32610

University of Florida, Gainesville

32803

Central Florida Pulmonary Group, Orlando

33136

University of Miami - Miller School of Medicine, Miami

33331

Cleveland Clinic Florida, Weston

33756

Bay Area Chest Physicians, Clearwater

34741

Pulmonary Disease Specialists (PDS) Research, Kissimmee

45267

University of Cincinnati / UC Health, Cincinnati

55905

Mayo Clinic, Rochester

63017

Cardio Pulmonary Research at St. Luke's Hospital, Chesterfield

75069

Metroplex Pulmonary and Sleep Center, McKinney

75708

University of Texas Health Science Center at Tyler, Tyler

78212

Alamo Clinical Research Associates, San Antonio

80202

National Jewish Health, Denver

85006

Pulmonary Associates, Phoenix

85012

Arizona Pulmonary Specialists, LTD, Phoenix

85013

St. Joseph's Hospital and Medical Center Heart and Lung Institute, Phoenix

85258

Arizona Pulmonary Specialists, Scottsdale

90095

David Geffen School of Medicine at UCLA, Los Angeles

93003

Landon Pediatric Foundation, Ventura

95817

UC Davis Medical Center Division of Pulmonary, Critical Care and Sleep Medicine, Sacramento

97239

Oregon Health and Science University, Portland

98104

Swedish Medical Center/Minor James Clinic, Seattle

98405

Multicare Pulmonary Specialist, Tacoma

06030

University of Connecticut Health Center, Farmington

T2N 4N1

University of Calgary, Calgary

T6G 2C8

University of Alberta, Edmonton

V1W 1V3

Kelowna Respiratory and Allergy Clinic, Kelowna

V5Z 1M9

The Lung Centre at Vancouver General Hospital, Vancouver

V6Z 1Y6

St. Paul's Hospital Pacific Lung Research, Vancouver

K7L 2V6

Kingston General Hospital / Queen's University, Kingston

M5B 1W8

St. Michael's Hospital, Toronto

N8X 5A6

Dr. Anil Dhar Private Practice, Windsor

H2W 1T8

Centre Hospitalier de L'Université de Montréal Hotel Dieu, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01313624 - Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | Biotech Hunter | Biotech Hunter